Cytokinetics(CYTK) - 2025 Q4 - Annual Results

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from ACACIA-HCM in Q2 2026 Company Provides 2026 Financial Guidance; ~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 SOUTH ...